• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

物理化学空间与最佳口服生物利用度:人体肠道吸收和首过消除的贡献。

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.

机构信息

Pharmacokinetics Dynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut 06340, USA.

出版信息

J Med Chem. 2010 Feb 11;53(3):1098-108. doi: 10.1021/jm901371v.

DOI:10.1021/jm901371v
PMID:20070106
Abstract

Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh). In this study, using a database comprised of Fa, Fg, Fh, and F values for 309 drugs in humans, an analysis of the interrelation of physicochemical properties and the individual parameters was carried out in order to define the physicochemical space for optimum human oral bioavailability. Trend analysis clearly indicated molecular weight (MW), ionization state, lipophilicity, polar descriptors, and free rotatable bonds (RB) influence bioavailability. These trends were due to a combination of effects of the properties on Fa and first-pass elimination (Fg and Fh). Higher MW significantly impacted Fa, while Fg and Fh decreased with increasing lipophilicity. Parabolic trends were observed for bioavailability with polar descriptors. Interestingly, RB has a negative effect on all three parameters, leading to its pronounced effect on bioavailability. In conclusion, physicochemical properties influence bioavailability with typically opposing effects on Fa and first-pass elimination. This analysis may provide a rational judgment on the physicochemical space to optimize oral bioavailability.

摘要

口服生物利用度(F)是吸收分数(Fa)、肠道壁消除分数(Fg)和肝脏消除分数(Fh)的乘积。在这项研究中,使用包含 309 个人类药物的 Fa、Fg、Fh 和 F 值的数据库,对理化性质和各个参数之间的相互关系进行了分析,以确定最佳人体口服生物利用度的理化空间。趋势分析清楚地表明,分子量(MW)、电离态、亲脂性、极性描述符和自由可旋转键(RB)影响生物利用度。这些趋势归因于这些性质对 Fa 和首过消除(Fg 和 Fh)的综合影响。较高的 MW 显著影响 Fa,而 Fg 和 Fh 随着亲脂性的增加而降低。生物利用度与极性描述符呈抛物线趋势。有趣的是,RB 对所有三个参数都有负面影响,这对生物利用度有显著影响。总之,理化性质影响生物利用度,对 Fa 和首过消除的影响通常相反。这种分析可以对优化口服生物利用度的理化空间进行合理判断。

相似文献

1
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.物理化学空间与最佳口服生物利用度:人体肠道吸收和首过消除的贡献。
J Med Chem. 2010 Feb 11;53(3):1098-108. doi: 10.1021/jm901371v.
2
In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.用于预测药物人体肠道吸收和首过消除的体外-体内外推法(IVIVE):原理与应用
Drug Dev Ind Pharm. 2014 Aug;40(8):989-98. doi: 10.3109/03639045.2013.831439. Epub 2013 Aug 28.
3
A comparison of pharmacokinetics between humans and monkeys.人与猴子之间的药代动力学比较。
Drug Metab Dispos. 2010 Feb;38(2):308-16. doi: 10.1124/dmd.109.028829. Epub 2009 Nov 12.
4
Oral bioavailability and first-pass effects.口服生物利用度和首过效应。
Drug Metab Dispos. 1997 Dec;25(12):1329-36.
5
[Biologic availability and "1st pass" effect of drugs].[药物的生物利用度和“首过”效应]
Fortschr Med. 1977 Jul 28;95(28):1765-6, 1774-80.
6
[The bioavailability of orally administered drugs with special regard to the liver as a filter for foreign matter].[口服给药的生物利用度,特别关注肝脏作为外来物质的过滤器]
Schweiz Med Wochenschr. 1980 Mar 8;110(10):354-62.
7
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.MEK抑制剂[14C]考比替尼在人体内的吸收、代谢、排泄以及肠道代谢对其口服处置的贡献。
Drug Metab Dispos. 2016 Jan;44(1):28-39. doi: 10.1124/dmd.115.066282. Epub 2015 Oct 8.
8
Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.一种用于预测体内口服生物利用度的新型体外Caco-2肝细胞杂交系统的评估。
Drug Metab Dispos. 2004 Sep;32(9):937-42.
9
ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints.药物发现中的 ADME 评估。9. 基于分子性质和结构指纹预测人体口服生物利用度。
Mol Pharm. 2011 Jun 6;8(3):841-51. doi: 10.1021/mp100444g. Epub 2011 May 16.
10
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique.采用新型灌注技术测定药物在人体肠壁和肝脏中的体内吸收、代谢及转运情况。
Clin Pharmacol Ther. 2001 Sep;70(3):217-27. doi: 10.1067/mcp.2001.117937.

引用本文的文献

1
Human intestinal enteroids: Nonclinical applications for predicting oral drug disposition, toxicity, and efficacy.人肠道类器官:预测口服药物处置、毒性和疗效的非临床应用。
Pharmacol Ther. 2025 May 19:108879. doi: 10.1016/j.pharmthera.2025.108879.
2
4-(1-Methylamino)ethylidene-1,5-disubstituted pyrrolidine-2,3-diones: synthesis, anti-inflammatory effect and in silico approaches.4-(1-甲氨基)亚乙基-1,5-二取代吡咯烷-2,3-二酮:合成、抗炎作用及计算机模拟方法
Beilstein J Org Chem. 2025 Apr 24;21:817-829. doi: 10.3762/bjoc.21.65. eCollection 2025.
3
Robust and reproducible human intestinal organoid-derived monolayer model for analyzing drug absorption.
用于分析药物吸收的强大且可重复的人肠道类器官衍生单层模型。
Sci Rep. 2025 Apr 3;15(1):11403. doi: 10.1038/s41598-025-95823-z.
4
Refined ADME Profiles for ATC Drug Classes.ATC药物分类的精准药代动力学/药物代谢特征
Pharmaceutics. 2025 Feb 28;17(3):308. doi: 10.3390/pharmaceutics17030308.
5
Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems.水凝胶与纳米凝胶:引领先进药物递送系统的未来
Pharmaceutics. 2025 Feb 7;17(2):215. doi: 10.3390/pharmaceutics17020215.
6
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.生物和小分子疗法的组织浓度在炎症性肠病临床研究中的应用
Pharmaceutics. 2024 Nov 22;16(12):1497. doi: 10.3390/pharmaceutics16121497.
7
Development of a novel gut microphysiological system that facilitates assessment of drug absorption kinetics in gut.一种新型肠道微生理系统的开发,该系统有助于评估肠道中的药物吸收动力学。
Sci Rep. 2024 Dec 2;14(1):29921. doi: 10.1038/s41598-024-80946-6.
8
Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.临床试验数据驱动的药物相互作用风险评估:一种快速准确的决策工具。
Clin Pharmacokinet. 2024 Aug;63(8):1147-1165. doi: 10.1007/s40262-024-01404-0. Epub 2024 Aug 5.
9
Exploration of Abiraterone acetate loaded Nanostructured lipid carriers for bioavailability improvement and circumvention of fast-fed variability.探索载有醋酸阿比特龙的纳米结构脂质载体以提高生物利用度并规避快速进食变异性。
Drug Deliv Transl Res. 2025 Mar;15(3):1074-1091. doi: 10.1007/s13346-024-01657-z. Epub 2024 Jul 12.
10
Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights.靶向 FXR 调节剂以实现肠道特异性:最新进展和研究进展。
Molecules. 2024 Apr 27;29(9):2022. doi: 10.3390/molecules29092022.